Salanersen
Sponsors
Biogen
Conditions
Muscular Atrophy, SpinalSpinal Muscular Atrophy
Phase 3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
RecruitingNCT07221669
Start: 2026-04-28End: 2032-05-29Target: 30Updated: 2026-08-18
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
RecruitingNCT07444476
Start: 2026-04-03End: 2032-06-22Target: 90Updated: 2026-04-21
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
RecruitingNCT07444450
Start: 2026-09-04End: 2033-07-26Target: 42Updated: 2026-08-11